Omnipaque™ (Iohexol)

Administered since 1982, this low osmolar contrast agent is indicated for intravenous, intra-arterial, intrathecal, body cavity and oral use in gastro-intestinal studies¹
Support

Scan after Scan

Over 1 Billion Omnipaque patient doses have been delivered since launch2

Prescribing Confidence

Lower incidence of acute adverse reactions (AAR) when compared with other contrast agents 3

Enhancing oral procedures

Patients preferred the taste of Omnipaque over barium sulfate contrast 4

Promoting workflow efficiency

Available in a range of bottle sizes, including 500mL, to suit all clinical needs
About Omnipaque™

Providing reliability and choice since 1982, Omnipaque is indicated for intravenous, intra-arterial, body cavity and gastro-intestinal studies1

Scan after scan

Supporting patient throughput with Omnipaque 500mL capacity

• 500ml should only be used with an auto-injector approved for this volume1
• Chemical & physical in-use stability for the 500ml has been demonstrated for 24hrs at 25oC1
• Multi-dose bottles help reduce waste of iodinated contrast media 7
Patient after patient

Omnipaque provides reliabilty and choice

• Indicated for intravenous, intra-arterial, body cavity, intrathecal and oral uses1
• Approved for use in both adults and children1
Study after study

Prescribing confidence with Omnipaque

• Systematic review & meta-analysis to assess AAR rates amongst LOCM 8
• Large dataset of 13,398,075 exposures 8
• Although AAR rates were low, there were significant differences between LOCM 8
• Omnipaque demonstrated the lowest rate for both moderate & severe reactions 8
Taste after Taste

Enhancing oral procedures with Omnipaque's palatability

• Palatability is a major reason for non-acceptance of oral CM and remains a core issue of non-compliance with the drink protocol 4
• Patients preferred Omnipaque over barium sulfate contrast 4
• Taste, consistency, and "less bloating" were the reasons behind Omnipaque being preferred by patients 4
• 98% of pediatric patients undergoing abdominal CT, many of whom were under the age of 5, drank the required volume of diluted Omnipaque 9
Bottle after Bottle

Omnipaque’s +PLUSPAK™ packaging support departmental efficiency

• Available in a variety of sizes to suit your all your clinical needs
• Easy to open flip top lid
• colour coding for different concentrations
• Peel-off tracking stickers
• Built-in hanger, with information easy to read upside and down
• +PLUSPAK™ has a 59% lower environmental impact than glass and decreases waste disposal costs10
References
1. Omnipaque product information, 20 December 2023
2. GE HealthCare, Data on File_ Patient Impact 2024
3. Gomi T et al. Eur Radiol 2010; 20(7): 1631-5
4. Parakh A et al. Radiology 2019; 291(3): 620–29.
5. Cheung Y-C et al. Eur Radiol 2014; 24(10): 2394-403.
6. Kamal RM et al. Eur J Radiol 2015; 84(6): 1049-55
7. Lindsey et al. Acad Radiol 2023; 30: 1017-23
8. Wei Y et al. EurRadiol 2025; doi: 1007/s00330-025-11526-z.
9. Smevik B, Westvik J. Acta Radiol 1990; 31(6): 601–4.
10. Dhaliwal et al. Int J Life Cycle Assess 2014; 19: 1965-73.

Omnipaque UK vial images are shown

JB01769AU February 2025